The role of hypoestrogenism in postmenopauseal osteoporosis: Perspectives;Papel del hipoestrogenismo en la osteoporosis posmenopáusica: Nuevas perspectivas

Ginecologia y Obstetricia de Mexico

Volumn 71, Issue APR., 2003, Pages 187-194

  Cárdenas Morales, Beatriz Eugenia ^a   Pérez Campos, Eduardo ^a  

^a NONE

Author keywords

Hypoestrogenism; Osteoporosis; Postmenopause

Indexed keywords

CYTOKINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

APOPTOSIS; BONE REMODELING; BONE TURNOVER; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; FEMALE; HUMAN; OSSIFICATION; OSTEOCYTE; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; AGED; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; APOPTOSIS; CARRIER PROTEINS; ESTROGENS; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOCYTES; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, ESTROGEN;

EID: 0042386197     PISSN: 03009041     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Albright F, Bloomberg F, Smith PH. Postmenopausal Osteoporosis. Trans Assoc Amer Phys 1940; 55: 298-305.
2. Riggs B.L., Melton U. Involutional Osteoporosis. N Engl J Med 1986; 314: 1676-84.
3. Consensus Development Conference. Proceedings of the World Congress on Osteoporosis. Amsterdam, May 18-23, 1996. Elsevier Science BV p 214-50.
4. Manolagas SC, Jilka RL. Bone marrow, cytokines and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-11.
5. Cummings SR, Black DM, Nevitt MC. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341: 72-5.
6. Denison E. The Epidemiology of osteoporosis. Br J Clin 1996; 50: 33-6.
7. Compston JE. Osteoporosis. J Clin Endoc Met 1990; 33: 653-82.
8. Aranda G, Barrón J, Ortega R, Pereyra R, Kably A. Un punto de vista fisiopatológico del climaterio y la menopausia. Ginec Obstet Mex 1998; 66: 253-9.
9. Murillo-Uribe A, Carranza S, Martínez N, Santos J. Variables epidemiológicas en la mujer posmenopáusica. Ginec Obstet Mex 1999; 67: 478-83.
10. Delmas PD. Clinical use of biochemical markers of bone remodeling. Bone 1992; 13: 513 (Abstract)
11. Kushida K, Takahashi M, Kawana K. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects and osteoporosis patients. J Clin Endoc Met 1994; 131: 369-74.
12. Cummings SR, Browner WS, Bauer D. From the Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339: 733-8.
13. Villegas C, Mayón J, González G, González M, Ibarra G, Murillo A, y cols. Estudio de la osteoporosis y osteopenia por medio de radiología, densitometría, morfometría y microscopía de barrido en la tercera vértebra lumbar en una muestra de hombres y mujeres en la ciudad de México. Ginec Obstet Mex 1998; 66: 187-201.
14. Hargrove JT, Eisenberg E. Menopause. Med Clin North Am 1995; 79: 1337-56.
15. a. Edición, España McGraw Hill Interamericana 1999. p. 823-44.
16. Ericksen EF, Colvard DS, Berg NJ, Graham M, Mann KG, Spelsberg TC, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988; 241: 84-6.
17. Paech K, Webb P, Kuiper GJM, Nilsson S, Gustafsson JA, Kushner PJ, et al. Differential ligand activation of estrogen receptors ER-alpha and ER-beta at AP1 sites. Science 1997; 277: 1508-10.
18. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G. et al. Human Estrogen Receptor beta-Gene Structure. Chromosomal Localization, and Expression Pattern. J Clin Endoc Met 1997; 82: 4258-65.
19. Hattersley G, Kerby JA, Chambers TJ. Identification of osteoclast precursors in multilineage hematopoietic colonies. Endocrinology 1991; 128: 259-62.
20. Horowitz MC. The rol of cytokines in bone remodeling. J Clin Dens 1998; 1: 187-98.
21. Jilka RL, Hangoc G, Girasole G. Increased osteoclast development after estrogen loss: mediation by Interleukin-6. Science 1992; 257: 88-91.
22. Cheleuitte D, Mizuno S, Glowacki J. In Vitro Secretion of Cytokines by Human Bone Marrow: Effects of Age and Estrogen Status. J Clin Endoc Met 1998; 86: 2043-51.
23. Bismar H, Diel I, Ziegler R, Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Cl Endoc Met 1995; 80: 3351-5.
24. Horowotz MC. Cytokines and estrogen in bone: antiosteoporotic effects. Science 1993; 260: 626-7.
25. Tomkinson A, Reeve J, Shaw RW, Noble BS. The Death of Osteocytes via Apoptosis accompanies Estrogen Withdrawal in Human Bone. J Clin Endoc Met 1997; 82: 3128-35.
26. Danowski WP, Rana N, Pepping G. Excretion of urinary in-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss. Fert Steril 1996; 66: 929-36.
27. Restwood KM, Fal PM, Clemens D. A comparison of the performance of serum and urine N-telopeptides of type 1 collage. 19th Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati Ohio. J Bone Miner Res 1997; 12: 144. Abstract.
28. Hofbauer LC, Heufelder A. The Role of Receptor Activator of Nuclear Factor-kB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. J Clin Endoc Met 2000; 85: 2355-63.
29. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140: 4367-70.
30. Lacey DL, Timmus E, Tan HL. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
31. Khosla S. et al. Effects of age and estrogen status on serum parathyroid hormone levels an biochemical markers of bone turnover in women. J Clin Endoc Met 1997; 82: 1522-7.
32. Ebeling PR et al Bone turnover markers and bone density across the menopausal transition. J Clin Endoc Met 1996; 81: 3366-71.
33. Khosla S, Melton III LJ, Atkinson EJ, OíFallon WM, KleeGG, RiggsBL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endoc Met 1998; 83: 2266-74.
34. Fonseca ME, Masón M, Ochoa R, Hernández M, Zárate A. Variaciones de las formas moleculares de la globulina transportadora de hormonas sexuales (SHBG) durante el ciclo menstrual y la menopausia. Ginec Obstet Mex 1996; 64: 508-16.
35. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993; 95: 37S-39S.
36. Santoro N. Therapeutic controversy: hormone replacement therapy: where are we going? J Cl Endoc Met 1999; 84: 1798-812.
37. Cummings SR, Nevitt M, Browner W, Stone K, Fox K, Ensrud K. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-73.
38. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Association between low levels of serum estradiol bone density and fractures among elderly women: The Study of Osteoporotic Fractures. J Cl Endoc Met 1998; 83: 2239-43.
39. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endoc Met 1979; 36: 207-14.
40. Kil Lim S, Jun Won Y, Jun J, Ho S, Jig B, Rae K. et al. Altered Hydroxilation of Estrogen in Patients with Postmenopausal Osteopenia. J Cl Endoc Met 1997; 82: 1001-6.